Catabasis Pharmaceuticals, Inc. (CATB)
Stock Price:
$1.93 USD
-0.16 (-7.66%)
Updated December 3, 4:00 PM EST - Market closed
After-hours: $1.98 +0.05 (2.59%) Dec 3, 7:45 PM
Key Info
| Market Cap |
38.76M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-34.93M |
| Shares Out |
19.42M |
| EPS (ttm) |
-2.14 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 3 |
| Last Price |
$1.93 |
| Previous Close |
$2.09 |
| Change ($) |
-0.16 |
| Change (%) |
-7.66% |
| Day's Open |
2.15 |
| Day's Range |
1.85 - 2.16 |
| Day's Volume |
13,933,014 |
| 52-Week Range |
1.32 - 8.20 |
More Stats
| Market Cap |
38.76M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.42M |
| Float |
n/a |
| EPS (basic) |
-2.14 |
| EPS (diluted) |
-2.14 |
| FCF / Share |
-1.66 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
444,224 |
| Short Ratio |
0.19 |
| Short % of Float |
n/a |
| Beta |
2.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
0.66 |
| Revenue |
n/a |
| Operating Income |
-35.21M |
| Net Income |
-34.93M |
| Free Cash Flow |
-32.23M |
| Net Cash |
51.65M |
| Net Cash / Share |
2.57 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-43.71% |
| ROE |
-79.77% |
| ROIC |
-195.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
0 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Low
24.0
Current: $1.93
High
24.0
Target: 24.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | 0.50 | - | - | - | - |
| Gross Profit | - | - | 0.50 | - | - | - | - |
| Operating Income | -27.09 | -26.37 | -27.09 | -35.56 | -31.66 | -21.68 | -18.12 |
| Net Income | -26.29 | -25.87 | -27.36 | -36.06 | -32.63 | -21.88 | -18.12 |
| Shares Outstanding | 11.20 | 5.05 | 2.17 | 1.62 | 0.80 | 0.04 | 0.04 |
| Earnings Per Share | -2.35 | -5.12 | -12.62 | -22.20 | -40.60 | -515.60 | -478.00 |
| Operating Cash Flow | -26.57 | -23.47 | -26.84 | -32.86 | -29.79 | -20.41 | -16.37 |
| Capital Expenditures | -0.01 | 0.37 | -0.03 | -0.41 | -0.42 | -0.23 | -0.04 |
| Free Cash Flow | -26.58 | -23.10 | -26.86 | -33.27 | -30.21 | -20.64 | -16.41 |
| Cash & Equivalents | 36.24 | 37.57 | 16.48 | 38.64 | 62.89 | 14.78 | 30.59 |
| Total Debt | 2.25 | - | 2.48 | 5.72 | 8.89 | 4.75 | - |
| Net Cash / Debt | 33.99 | 37.57 | 14.00 | 32.92 | 54.00 | 10.03 | 30.59 |
| Assets | 41.78 | 39.17 | 17.90 | 40.21 | 64.17 | 15.96 | 31.00 |
| Liabilities | 6.06 | 4.23 | 6.11 | 11.12 | 13.68 | 8.87 | 83.19 |
| Book Value | 35.72 | 34.94 | 11.79 | 29.09 | 50.49 | -73.05 | -52.18 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Catabasis Pharmaceuticals, Inc. |
| Employees |
27 |
Stock Information
| Ticker Symbol |
CATB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CATB |
| IPO Date |
June 25, 2015 |
Description
Catabasis Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.